James D. Bergstrom - Concepedia

Author

James D. Bergstrom

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also Known As

J BERGSTROM, J D Bergstrom, J D Bergström, J. BERGSTROM, J. Bergstrom, J. Bergström, J. D. BERGSTROM, J. D. Bergstrom, J. Daniel Bergström, J.D. Bergstrom

Publications

5.9K

Citations

H-Index

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)University of California, Los Angeles United States Military Academy

About

James D. Bergstrom is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in biochemistry, medicine, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	21	26	3.1K
2	Natural Sciences	17	20	1.6K
3	Engineering	3	3	67
4	Health Sciences	2	2	130
5	Education	1	1	30

James D. Bergstrom

Publications

5.6K

Citations

H-Index

Page 1

	Year	Citations
Alteration of Lymphocyte Trafficking by Sphingosine-1-Phosphate Receptor Agonists Suzanne Mandala, Richard Hajdu, James D. Bergstrom, Science Lymphocyte DevelopmentImmunologyImmunologic MechanismImmunotherapyLymphoid Sinuses	2002	1.7K
Alendronate Is a Specific, Nanomolar Inhibitor of Farnesyl Diphosphate Synthase James D. Bergstrom, Richard G. Bostedor, P. Masarachia, Archives of Biochemistry and Biophysics BiochemistryNatural SciencesBiocatalysisDrug DiscoveryEnzyme Catalysis	2000	398
Capacity for substrate utilization in oxidative metabolism by neurons, astrocytes, and oligodendrocytes from developing brain in primary culture John Edmond, Richard Robbins, James D. Bergstrom, Journal of Neuroscience Research	1987	362
Zaragozic acids: a family of fungal metabolites that are picomolar competitive inhibitors of squalene synthase. James D. Bergstrom, Marc M. Kurtz, Deborah J. Rew, Proceedings of the National Academy of Sciences BiosynthesisNatural Product SynthesisBiochemistrySqualene SynthaseNatural Sciences	1993	334
Immune Cell Regulation and Cardiovascular Effects of Sphingosine 1-Phosphate Receptor Agonists in Rodents Are Mediated via Distinct Receptor Subtypes M J Forrest, S.-Y. Sun, Richard Hajdu, Journal of Pharmacology and Experimental Therapeutics	2004	332
Polyisoprenylation of Ras in vitro by a farnesyl-protein transferase. Michael D. Schaber, Masayuki Ohara, V M Garsky, Journal of Biological Chemistry BiochemistryNatural SciencesDrug DiscoveryBioanalysisCaax Box	1990	226
Deficiency in Inducible Nitric Oxide Synthase Results in Reduced Atherosclerosis in Apolipoprotein E-Deficient Mice Patricia A. Detmers, Melba Hernandez, John S. Mudgett, The Journal of Immunology	2000	207
Molecular cloning and characterization of a lipid phosphohydrolase that degrades sphingosine-1- phosphate and induces cell death Suzanne Mandala, Rosemary Thornton, Ismael Galve‐Roperh, Proceedings of the National Academy of Sciences	2000	194
Infectious Agents Are Not Necessary for Murine Atherogenesis Samuel D. Wright, Charlotte Burton, Melba Hernandez, The Journal of Experimental Medicine InflammationHost ResponsePathogenicityInfectious AgentsPathogenesis	2000	176
Discovery of Potent 3,5-Diphenyl-1,2,4-oxadiazole Sphingosine-1-phosphate-1 (S1P<sub>1</sub>) Receptor Agonists with Exceptional Selectivity against S1P<sub>2</sub> and S1P<sub>3</sub> Zhen Li, Weirong Chen, Jeffrey J. Hale, Journal of Medicinal Chemistry Drug TargetImmunologyPharmacotherapyS1p3 Receptor AgonismMolecular Pharmacology	2005	99

Page 1